COVID-19 Convalescent Plasma Therapy: Long-term Implications
Author:
Yoon Hyunah1, Li Yi2, Goldfeld Keith S2, Cobb Gia F3, Sturm-Reganato Caroline L3, Ostrosky-Zeichner Luis4ORCID, Jayaweera Dushyantha T56, Philley Julie V7, Desruisseaux Mahalia S8, Keller Marla J19, Hochman Judith S10, Pirofski Liise-anne111ORCID, Ortigoza Mila B1213ORCID, Hochman Judith S, Cronstein Bruce N, Keeling Deborah, Rappoport Norka, Saraga Jenna, Holahan James, Ortigoza Mila B, Pirofski Liise-anne, Yoon Hyunah, Sturm-Reganato Caroline L, Cobb Gia F, Andela Rakshit, Darwish Yousef, Taveras Monica R, Xin Patrick S, LaFleur Jeff, Cleare Levi, Goldfeld Keith S, Li Yi, Ortigoza Mila B, O'Keeffe Mary L, Cobb Gia F, Sturm-Reganato Caroline L, Rahman Fatema Z, Ajayi Adeyinka O, Rodriguez Sara L, Iturrate Eduardo, Gallagher Jacqueline M, Thomas Ololade E, Ramos Danibel, Fong Charlotte C, Pirofski Liise-anne, Yoon Hyunah, Keller Marla J, Asencio Andrea A, Eke Isaiah, Castro James, Shan Jidong, Chalco Alex, LaFleur Jeff, Cleare Levi, Desruisseaux Mahalia, Cortezzo Grace M, Rocco Erica, Ndunge Oscar Bate Akide, Parmelee Catherine, Solomon Gina, Cahil Staci, Jayaweera Dushyantha T, Lee Chin Chin, Ransford Daru L, Dasmany Deniz, Corona Andres, Moreno Kenia, Martinez Gledys L, Otero Christopher, McPherson David D, Ostrosky-Zeichner Luis, Patel Bela, Nigo Masayuki, Huebinger Ryan M, Dronavalli Goutham, Grimes Carolyn Z, Umana Virginia E, Hernandez Maria D, Nielsen Laura E, Stutz Taylor P, Mammadova Mehriban, Dentino Andrew N, Heath Timothy R, Martin Jessica G, Bello Fatimah O, Hinojosa Erik, Philley Julie V, Devine Megan S, Hibbard Rebekah L, Ford Anne M,
Affiliation:
1. Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center , Bronx, New York , USA 2. Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine , New York, New York , USA 3. Department of Medicine, NYU Grossman School of Medicine , New York, New York , USA 4. Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School , Houston, Texas , USA 5. Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine , Miami, Florida , USA 6. Miami Clinical and Translational Science Institute, University of Miami Miller School of Medicine, Miami , Florida , USA 7. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Tyler, UTHealth East Texas , Tyler, Texas , USA 8. Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine , New Haven, Connecticut , USA 9. Harold and Muriel Block Institute for Clinical and Translational Research, Albert Einstein College of Medicine and Montefiore Medical Center , Bronx, New York , USA 10. Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine , New York, New York , USA 11. Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York , USA 12. Division of Infectious Diseases, Department of Medicine, NYU Grossman School of Medicine , New York, New York , USA 13. Department of Microbiology, NYU Grossman School of Medicine , New York, New York , USA
Abstract
Abstract
Background
The long-term effect of coronavirus disease 2019 (COVID-19) acute treatments on postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) is unknown. The CONTAIN-Extend study explores the long-term impact of COVID-19 convalescent plasma (CCP) therapy on postacute sequelae of SARS-CoV-2 infection (PASC) symptoms and general health 18 months following hospitalization.
Methods
The CONTAIN-Extend study examined 281 participants from the original CONTAIN COVID-19 trial (CONTAIN-RCT, NCT04364737) at 18 months post–hospitalization for acute COVID-19. Symptom surveys, global health assessments, and biospecimen collection were performed from November 2021 to October 2022. Multivariable logistic and linear regression estimated associations between the randomization arms and self-reported symptoms and Patient-Reported Outcomes Measurement Information System (PROMIS) scores and adjusted for covariables, including age, sex, race/ethnicity, disease severity, and CONTAIN enrollment quarter and sites.
Results
There were no differences in symptoms or PROMIS scores between CCP and placebo (adjusted odds ratio [aOR] of general symptoms, 0.95; 95% CI, 0.54–1.67). However, females (aOR, 3.01; 95% CI, 1.73–5.34), those 45–64 years (aOR, 2.55; 95% CI, 1.14–6.23), and April–June 2020 enrollees (aOR, 2.39; 95% CI, 1.10–5.19) were more likely to report general symptoms and have poorer PROMIS physical health scores than their respective reference groups. Hispanic participants (difference, −3.05; 95% CI, −5.82 to −0.27) and Black participants (−4.48; 95% CI, −7.94 to −1.02) had poorer PROMIS physical health than White participants.
Conclusions
CCP demonstrated no lasting effect on PASC symptoms or overall health in comparison to the placebo. This study underscores the significance of demographic factors, including sex, age, and timing of acute infection, in influencing symptom reporting 18 months after acute hypoxic COVID-19 hospitalization.
Funder
NCATS NIH New York University Albert Einstein College of Medicine Yale University University of Miami University of Texas Health Sciences Center Houston
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Oncology
|
|